VNDA

Vanda Pharmaceuticals Inc. - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2007. Vanda Pharmaceuticals Inc. is a biopharmaceutical company in the development stage, focused on small molecule therapeutics for central nervous system disorders. The company has no approved products and no product revenues to date. Its primary activities involve the development of three clinical-stage product candidates: iloperidone (schizophrenia/bipolar disorder), VEC-162 (sleep/mood disorders), and VSF-173 (excessive sleepiness). On September 27, 2007, the company submitted a New Drug Application (NDA) for iloperidone to the FDA.

Key Financial Metrics

Accumulated Deficit: Since inception (March 13, 2003) through September 30, 2007, the company has accumulated a deficit of approximately $153.16 million.

Material Changes vs. Prior Period

• Revenue: The company generated no product revenue in the current or prior periods. A nominal amount of $71,345 was recognized as "Other Income" from a grant in the current quarter.
• Operating Expenses: Total operating expenses increased by 84% to $23.52 million for the three months ended September 30, 2007, compared to $12.81 million in the same period in 2006.
  • R&D Expenses: Increased 45% to $13.87 million (Q3 2007) vs. $9.54 million (Q3 2006). This increase was driven by a $5.0 million milestone license fee payable to Novartis for the iloperidone NDA filing and increased manufacturing costs, partially offset by lower clinical trial expenses as Phase III trials for iloperidone and VEC-162 were largely completed in 2006.
  • G&A Expenses: Increased 196% to $9.65 million (Q3 2007) vs. $3.26 million (Q3 2006). This surge was primarily due to increased stock-based compensation ($4.06 million vs. $1.32 million) and marketing/consulting services ($3.37 million vs. $0.24 million) in preparation for the commercial launch of iloperidone.
• Liquidity: Cash and cash equivalents increased from $30.93 million at December 31, 2006, to $59.95 million at September 30, 2007. Total liquid assets (cash + marketable securities) grew from approximately $31.9 million to $109.4 million, largely due to net proceeds of $111.3 million from a follow-on common stock offering in January 2007.

Guidance, Outlook, and Risks

• Capital Resources: Management believes current capital resources will be sufficient to meet anticipated operating needs into mid-2008. The company expects to require additional capital thereafter to fund operations and commercialization efforts.
• Product Pipeline:
  • Iloperidone: NDA submitted for schizophrenia. Commercial launch expected in early 2009 pending FDA approval. Development of a 4-week injectable formulation is ongoing.
  • VEC-162: Phase III trial for chronic primary insomnia initiated in October 2007; results expected in Q4 2008. Ready for Phase II trials for depression.
  • VSF-173: Top-line results of first Phase II trial for excessive sleepiness reported in October 2007. Additional Phase II trials planned.
• Risks:
  • Regulatory Approval: No guarantee that the FDA will accept the iloperidone NDA or approve any product candidates. Delays or rejections would materially harm the business.
  • Capital Needs: Failure to secure additional funding after mid-2008 could force the company to delay, scale back, or eliminate R&D activities or enter into unfavorable collaboration agreements.
  • Intellectual Property: Rights to product candidates are subject to license agreements with Novartis and Bristol-Myers Squibb. Failure to meet milestones or financial obligations could result in the loss of rights to these assets.
  • Market Acceptance: Even with approval, products may fail to achieve market acceptance or reimbursement.

Investor Verification Checklist

• NDA Filing Status: Verify the FDA's acceptance of the iloperidone NDA submitted on September 27, 2007, and any subsequent correspondence regarding review timelines.
• Cash Runway: Confirm the company's burn rate and the sufficiency of the $109.4 million in liquid assets to sustain operations through mid-2008 without further dilution.
• Milestone Obligations: Review the specific terms of the license agreements with Novartis and BMS to understand future cash outflows tied to regulatory approvals and sales milestones.
• Stock-Based Compensation: Assess the impact of the significant increase in stock-based compensation ($14.3 million for the nine months ended Sep 2007) on future expense projections and potential dilution.
• Clinical Trial Results: Monitor the upcoming Phase III results for VEC-162 (expected Q4 2008) and further Phase II data for VSF-173.